Forkhead‑box series expression network is associated with outcome of clear‑cell renal cell carcinoma

Jia,Zhongwei; Wan,Fangning; Zhu,Yao; Shi,Guohai; Zhang,Hailiang; Dai,Bo; Ye,Dingwei

doi:10.3892/ol.2018.8405

Forkhead‑box series expression network is associated with outcome of clear‑cell renal cell carcinoma

Authors:
- Zhongwei Jia
- Fangning Wan
- Yao Zhu
- Guohai Shi
- Hailiang Zhang
- Bo Dai
- Dingwei Ye
View Affiliations

Affiliations: Department of Urology, Fudan University Shanghai Cancer Center, Shanghai 200032, P.R. China
Published online on: April 2, 2018 https://doi.org/10.3892/ol.2018.8405
Pages: 8669-8680

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous studies have demonstrated that several members of the Forkhead‑box (FOX) family of genes are associated with tumor progression and metastasis. The objective of the current study was to screen candidate FOX family genes identified from analysis of molecular networks in clear cell renal cell carcinoma (ccRCC). The expression of FOX family genes as well as FOX family‑associated genes was examined, and Kaplan‑Meier survival analysis was performed in The Cancer Genome Atlas (TCGA) cohort (n=525). Patient characteristics, including sex, age, tumor diameter, laterality, tumor‑node‑metastasis, tumor grade, stage, white blood cell count, platelet count, the levels of hemoglobin, overall survival (OS) and disease‑free survival (DFS), were collected for univariate and multivariate Cox proportional hazards ratio analyses. A total of seven candidate FOX family genes were selected from the TCGA database subsequent to univariate and multivariate Cox proportional hazards ratio analyses. FOXA1, FOXA2, FOXD1, FOXD4L2, FOXK2 and FOXL1 were associated with poor OS time, while FOXA1, FOXA2, FOXD1 and FOXK2 were associated with poor DFS time (P<0.05). FOXN2 was associated with favorable outcomes for overall and disease‑free survival (P<0.05). In the gene cluster network analysis, the expression of FOX family‑associated genes, including nuclear receptor coactivator (NCOA)1, NADH‑ubiquinone oxidoreductase flavoprotein 3 (NDUFV3), phosphatidylserine decarboxylase (PISD) and pyruvate kinase liver and red blood cell (PKLR), were independent prognostic factors for OS in patients with ccRCC. Results of the present study revealed that the expression of FOX family genes, including FOXA1, FOXA2, FOXD1, FOXD4L2, FOXK2 and FOXL1, and FOX family‑associated genes, including NCOA1, NDUFV3, PISD and PKLR, are independent prognostic factors for patients with ccRCC.

View Figures

View References

1	Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Carducci MA, Chang SS, Choueiri TK, Hancock SL, Hudes GR, et al: Kidney cancer. J Natl Compr Canc Netw. 9:960–977. 2011. View Article : Google Scholar : PubMed/NCBI
2	Ljungberg B, Campbell SC, Cho HY, Jacqmin D, Lee JE, Weikert S and Kiemeney LA: The epidemiology of renal cell carcinoma. Eur Urol. 60:615–621. 2011. View Article : Google Scholar : PubMed/NCBI
3	Gudbjartsson T, Hardarson S, Petursdottir V, Thoroddsen A, Magnusson J and Einarsson GV: Histological subtyping and nuclear grading of renal cell carcinoma and their implications for survival: A retrospective nation-wide study of 629 patients. Eur Urol. 48:593–600. 2005. View Article : Google Scholar : PubMed/NCBI
4	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar : PubMed/NCBI
5	Han S, Wang T, Jiang D, Yu Y, Wang Y, Yan W, Xu W, Cheng M, Zhou W and Xiao J: Surgery and survival outcomes of 30 patients with neurological deficit due to clear cell renal cell carcinoma spinal metastases. Eur Spine J. 24:1786–1791. 2015. View Article : Google Scholar : PubMed/NCBI
6	Almeida M, Han L, Martin-Millan M, O'Brien CA and Manolagas SC: Oxidative stress antagonizes Wnt signaling in osteoblast precursors by diverting beta-catenin from T cell factor-to Forkhead Box O-mediated transcription. J Biol Chem. 282:27298–27305. 2007. View Article : Google Scholar : PubMed/NCBI
7	Brenkman AB, van den Broek NJF, de Keizer PLJ, van Gent DC and Burgering BM: The DNA damage repair protein Ku70 interacts with FOXO4 to coordinate a conserved cellular stress response. FASEB J. 24:4271–4280. 2010. View Article : Google Scholar : PubMed/NCBI
8	Roesch A, Mueller AM, Stempfl T, Moehle C, Landthaler M and Vogt T: RBP2-H1/JARID1B is a transcriptional regulator with a tumor suppressive potential in melanoma cells. Int J Cancer. 122:1047–1057. 2008. View Article : Google Scholar : PubMed/NCBI
9	Katoh M and Katoh M: Human FOX gene family (Review). Int J Oncol. 25:1495–1500. 2004.PubMed/NCBI
10	Lu X, Wan F, Zhang H, Shi G and Ye D: ITGA2B and ITGA8 are predictive of prognosis in clear cell renal cell carcinoma patients. Tumour Biol. 37:253–262. 2016. View Article : Google Scholar : PubMed/NCBI
11	Paner GP, Stadler WM, Hansel DE, Montironi R, Lin DW and Amin MB: Updates in the eighth edition of the tumor-node-metastasis staging classification for urologic cancers. Eur Urol: pii: S0302-2838. 2018.
12	Reddy OL, Cates JM, Gellert LL, Crist HS, Yang Z, Yamashita H, Taylor JA III, Smith JA Jr, Chang SS, Cookson MS, et al: Loss of FOXA1 drives sexually dimorphic changes in Urothelial differentiation and is an independent predictor of poor prognosis in bladder cancer. Am J Pathol. 185:1385–1395. 2015. View Article : Google Scholar : PubMed/NCBI
13	Guo W, Keener AL, Jing Y, Cai L, Ai J, Zhang J, Fisher AL, Fu G and Wang Z: FOXA1 modulates EAF2 regulation of AR transcriptional activity, cell proliferation and migration in prostate cancer cells. Prostate. 75:976–987. 2015. View Article : Google Scholar : PubMed/NCBI
14	Zheng L, Qian B, Tian D, Tang T, Wan S, Wang L, Zhu L and Geng X: FOXA1 positively regulates gene expression by changing gene methylation status in human breast cancer MCF-7 cells. Int J Clin Exp Pathol. 8:96–106. 2015.PubMed/NCBI
15	Dou C, Wang Y, Li C, Liu Z, Jia Y, Li Q, Yang W, Yao Y, Liu Q and Tu K: MicroRNA-212 suppresses tumor growth of human hepatocellular carcinoma by targeting FOXA1. Oncotarget. 6:13216–13228. 2015. View Article : Google Scholar : PubMed/NCBI
16	Yang YA and Yu J: Current perspectives on FOXA1 regulation of androgen receptor signaling and prostate cancer. Genes Dis. 2:144–151. 2015. View Article : Google Scholar : PubMed/NCBI
17	Gosalia N, Yang R, Kerschner JL and Harris A: FOXA2 regulates a network of genes involved in critical functions of human intestinal epithelial cells. Physiol Genomics. 47:290–297. 2015. View Article : Google Scholar : PubMed/NCBI
18	Perez-Balaguer A, Ortiz-Martínez F, García-Martínez A, Pomares-Navarro C, Lerma E and Peiró G: FOXA2 mRNA expression is associated with relapse in patients with triple-negative/basal-like breast carcinoma. Breast Cancer Res Treat. 153:465–474. 2015. View Article : Google Scholar : PubMed/NCBI
19	Zhu C, Wang J, Shi B, Hu P, Ning B, Zhang Q, Chen F, Chen WS, Zhang X and Xie WF: The transcription factor FOXA2 suppresses gastric tumorigenesis in vitro and in vivo. Digest Dis Sci. 60:109–117. 2015. View Article : Google Scholar : PubMed/NCBI
20	Zhao YF, Zhao JY, Yue H, Hu KS, Shen H, Guo ZG and Su XJ: FOXD1 promotes breast cancer proliferation and chemotherapeutic drug resistance by targeting p27. Biochem Biophys Res Commun. 456:232–237. 2015. View Article : Google Scholar : PubMed/NCBI
21	Nakayama S, Soejima K, Yasuda H, Yoda S, Satomi R, Ikemura S, Terai H, Sato T, Yamaguchi N, Hamamoto J, et al: FOXD1 expression is associated with poor prognosis in non-small cell lung cancer. Anticancer Res. 35:261–268. 2015.PubMed/NCBI
22	Van der Heul-Nieuwenhuijsen L, Dits NF and Jenster G: Gene expression of forkhead transcription factors in the normal and diseased human prostate. BJU Int. 103:1574–1580. 2009. View Article : Google Scholar : PubMed/NCBI
23	Ji Z, Donaldson IJ, Liu J, Hayes A, Zeef LA and Sharrocks AD: The forkhead transcription factor FOXK2 promotes AP-1-mediated transcriptional regulation. Mol Cell Biol. 32:385–398. 2012. View Article : Google Scholar : PubMed/NCBI
24	Zhang G, He P, Gaedcke J, Ghadimi BM, Ried T, Yfantis HG, Lee DH, Hanna N, Alexander HR and Hussain SP: FOXL1, a novel candidate tumor suppressor, inhibits tumor aggressiveness and predicts outcome in human pancreatic cancer. Cancer Res. 73:5416–5425. 2013. View Article : Google Scholar : PubMed/NCBI
25	Robertson E, Perry C, Doherty R and Madhusudan S: Transcriptomic profiling of Forkhead box transcription factors in adult glioblastoma multiforme. Cancer Genomics Proteomics. 12:103–112. 2015.PubMed/NCBI
26	Qin L, Wu YL, Toneff MJ, Li D, Liao L, Gao X, Bane FT, Tien JC, Xu Y, Feng Z, et al: NCOA1 directly targets M-CSF1 expression to promote breast cancer metastasis. Cancer Res. 74:3477–3488. 2014. View Article : Google Scholar : PubMed/NCBI
27	De Coo RF, Buddiger P, Smeets HJ and van Oost BA: Molecular cloning and characterization of the human mitochondrial NADH: Oxidoreductase 10-kDa gene (NDUFV3). Genomics. 45:434–437. 1997. View Article : Google Scholar : PubMed/NCBI
28	Kim JC, Kim SY, Roh SA, Cho DH, Kim DD, Kim JH and Kim YS: Gene expression profiling: Canonical molecular changes and clinicopathological features in sporadic colorectal cancers. World J Gastroenterol. 43:6662–6672. 2008. View Article : Google Scholar
29	Park-Hah JO, Kanno H, Kim WD and Fujii H: A novel homozygous mutation of PKLR gene in a pyruvate-kinase-deficient korean family. Acta Haematol. 113:208–211. 2005. View Article : Google Scholar : PubMed/NCBI
30	Li P, Wong YN, Jahnke J, Pettit AR and Doshi JA: Association of high cost sharing and targeted therapy initiation among elderly Medicare patients with metastatic renal cell carcinoma. Cancer Med. 1:75–86. 2018. View Article : Google Scholar
31	Hakimi AA, Reznik E, Lee CH, Creighton CJ, Brannon AR, Luna A, Aksoy BA, Liu EM, Shen R, Lee W, et al: An integrated metabolic atlas of clear cell renal cell carcinoma. Cancer Cell. 1:104–116. 2016. View Article : Google Scholar